Inflammatory Bowel Disease

In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent how to choose the right ulcerative colitis treatment for the right patient.

DENVER — Patients with inflammatory bowel disease and non-ST elevation myocardial infarction had higher mortality, hospital stays and hospital charges than patients with IBD alone, noted a presenter at the Crohn’s and Colitis Congress.

Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.

DENVER — Although the use of artificial intelligence for inflammatory bowel disease can reasonably replicate expert judgment and predict outcomes, clinicians must retain the ability to intervene and “take control” when the AI is wrong.

DENVER — Hyperbaric oxygen therapy yielded a clinical response rate of 87% among patients with fistulizing Crohn’s disease with few adverse events, according to systematic review data presented at the Crohn’s and Colitis Congress.

DENVER — The combination of herbal extracts curcumin and QingDai induced clinical response and remission in patients with active ulcerative colitis, according to data presented at the Crohn’s and Colitis Congress.

The past year has seen quite a few new developments in inflammatory bowel disease therapy.

In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

Antibiotic exposure was associated with an increased and cumulative risk for inflammatory bowel disease and was highest among individuals aged 40 years and older, according to results from a Danish study published in Gut.

Topline findings from the phase 2 ARTEMIS-UC and phase 2a APOLLO-CD trials showed that PRA023, an anti-TL1A monoclonal antibody, was safe and effective for Crohn’s disease and ulcerative colitis, Prometheus Biosciences announced.